Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2026

Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo's 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relati.

Business Wire • Aug 31, 2026

Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?

BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.

Zacks Investment Research • Aug 21, 2026

Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?

BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.

Zacks Investment Research • Aug 20, 2026

Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock

Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Zacks Investment Research • Aug 10, 2026

Bio-Rad Laboratories Q2 Earnings Call Highlights

Bio-Rad Laboratories NYSE: BIO reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral basis, as continued softness in academic research markets weighed on its Life Science segment.

MarketBeat • Aug 5, 2026

Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026

Bio-Rad Reports Second-Quarter 2026 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR.

Business Wire • Aug 4, 2026

Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.34 per share. This compares to earnings of $2.61 per share a year ago.

Zacks Investment Research • Aug 5, 2026

Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2026 on Tuesday, August 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.

Business Wire • Jul 23, 2026